about
Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cellsBRCA1 haploinsufficiency for replication stress suppression in primary cellsRadiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancerCancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization TechnologyA microfluidic device for label-free, physical capture of circulating tumor cell clusters.EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer.Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells.Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinomaInertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.P53 and the defenses against genome instability caused by transposons and repetitive elementsHER2 expression identifies dynamic functional states within circulating breast cancer cells.Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer.An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.Branched-chain in situ hybridization for κ and λ light chains: A powerful ancillary technique for determining B-cell clonality in cytology samples.PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination.The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28.The Human Long Interspersed Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia.Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.Performance of a Branch Chain RNA In Situ Hybridization Assay for the Detection of High-risk Human Papillomavirus in Head and Neck Squamous Cell Carcinoma.Microsatellite instability in gallbladder carcinoma.Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition.Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.Expression of Albumin mRNA in Primary Hepatic Neoplasms and Acinar Cell CarcinomaThe wide gulf between stage III and stage IV colon cancerDeregulation of ribosomal protein expression and translation promotes breast cancer metastasisLiquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersNo Cell Left Unturned: Intraductal Papillary Mucinous Neoplasm HeterogeneityRole of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs)Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersTAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
P50
Q33668714-E19D8B8A-B203-4C8C-A938-901BCE9DE883Q34111187-3E1C39C6-15D1-4E1B-8B2A-A2C29B7CE6DDQ34494714-9B94D70B-8A97-48A0-8BDE-0A84AC35117CQ34502783-3A911B01-3F44-464C-B040-26D304EF0534Q34568339-06656E59-1F54-48DB-BDB5-9DF751896B9FQ35147520-AA36B81C-7FE4-47AC-88F8-0599768190AAQ35174681-C9D620CB-4957-47AC-82F9-9425180661CAQ35756580-024C9993-84BE-4D1C-8AC1-14CDAC0CDA26Q35812039-B7E27A92-D832-4031-8632-5DAD4662EA78Q35820934-972A23B8-4B24-468E-A580-6E09678CD69DQ36371398-BAB16976-3C0F-4A0A-8829-B68026167B80Q36371484-139802BB-A2FE-4ED8-995B-1E5D230ECA82Q36422370-13E31CAE-C193-4881-BB05-0852AAE1532DQ36848514-880F6D3A-EAD7-4AC5-BE3F-390A72E9DBCFQ37140168-AE0B8570-9AA8-4083-9A33-A610C5B8EA61Q37272469-27E8D853-BB78-4613-805E-7A188F4565BFQ37510512-C365BE00-D1D5-4F90-8847-E90FC3F18EDAQ37624345-3E8508B3-2FF7-41AF-9336-306BA2F7094FQ37626208-1BD07E76-2BFC-4E2A-ACA2-590F8FFA9BDBQ37630804-22CDA118-6AC2-4E47-AE75-1804A30A0E1BQ37630808-ED7375E6-8B1A-46E1-BE98-99ABDCED1B89Q37660683-5A18C45B-B52C-498F-9C1B-8041F792EF6AQ38886016-F936C581-8987-4697-988B-58C6B9108F86Q39130945-483C212B-9C92-40C4-9421-CA610F58F046Q39254330-4304ADCE-46F0-4E12-9B4D-CEEB0B73DDCBQ39884529-8B6C2D9D-0129-49EE-9F27-B6C4DEBDCC84Q40971090-84D186F5-B6B3-4DBA-978C-30069AB68EF4Q41438298-A9EAAA7C-ED0E-4479-829E-29ACC0D61A85Q50231325-A6E6AD2A-7C56-43EF-AF1A-79D29A5212AEQ53063479-FE5CCE79-E271-4C35-B7BF-CA07C1FA6773Q64974096-DBC5D33D-6F1C-415F-9F40-C9B6DB665542Q85587146-F6A2D3B2-C6D3-4113-9786-636D3EAA1384Q88076744-E9063642-DF21-490C-8CC9-00E54EA12D7BQ89582237-9073CBA1-4579-48F8-94F9-1B2EA77D05BCQ90003849-9D67AB14-428F-4E7C-B0E7-A15941EC4555Q91044300-FF938C4C-C270-4047-BBF7-2E34A119DA5DQ91167424-0761AE82-5E77-4C36-A4EA-F02DDA81D9C4Q91345393-F572ED57-4A13-47A1-85FD-7B350E65FCF1Q92169606-D9D88E98-AB0E-4FE8-AE68-8CC328998DE7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David T Ting
@ast
David T Ting
@en
David T Ting
@es
David T Ting
@nl
David T Ting
@sl
type
label
David T Ting
@ast
David T Ting
@en
David T Ting
@es
David T Ting
@nl
David T Ting
@sl
prefLabel
David T Ting
@ast
David T Ting
@en
David T Ting
@es
David T Ting
@nl
David T Ting
@sl
P106
P21
P31
P496
0000-0002-3261-2322